3000 patients on biosimilar (PERFUSE study)

We at Sanoïa are pleased to announce that the PERFUSE study has been successfully expanded to include a second biosimilar treatment and twice as much patients! In addition, a new direct-to-patient data collection service has been deployed to measure patient experience when switching treatment.

A biosimilar is a biological medicine (a medicine whose active substance is made by a living organism) highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines.


e-Health Services SAS


  • LinkedIn Social Icône


(French Clinical Research Association)

Sanoïa is an agile Contract Research Organization for tailor-made Real-Life studies.